Gestational Diabetes: Effective Treatment and Prevention of Complications

What is gestational diabetes and why is it important?

Gestational diabetes mellitus (GDM) is a carbohydrate metabolism disorder that is first detected or occurs during pregnancy. This condition is one of the most common complications of pregnancy and carries significant risks for both maternal health and fetal development [1, 6].

GDM is not just a temporary rise in blood sugar; it is a "signaling metabolic event" that indicates pre-existing impairments in pancreatic beta-cell function and insulin sensitivity [6]. During pregnancy, physiological insulin resistance increases, reaching a 60-65% reduction in insulin sensitivity by the third trimester. To maintain normal glucose levels, the pancreas must increase insulin production by 200-250%. If beta-cells cannot cope with this load, maternal hyperglycemia develops, leading to fetal hyperinsulinemia. This creates an intrauterine environment that promotes accelerated fetal growth, fat accumulation, and adverse metabolic programming [6].

The consequences of GDM can be serious:

• For the mother: increased risk of preeclampsia, cesarean section, and a high risk of developing type 2 diabetes mellitus (T2DM) in the future [3, 6].
• For the child: macrosomia (large fetus), hypoglycemia after birth, respiratory distress syndrome, and an increased risk of developing obesity and T2DM throughout life [6]. Studies also show that intrauterine exposure to maternal diabetes, including GDM, is associated with an increased risk of seborrheic dermatitis in offspring (4.9% compared to 4.5% in the general population) [5].

Diagnosis and management basics

Diagnosis of GDM is typically performed using a glucose tolerance test at 24-28 weeks of pregnancy. Once diagnosed, the first line of therapy is always lifestyle modification:

• Dietary therapy: an individually tailored meal plan with carbohydrate control.
• Physical activity: moderate, regular exercise approved by a physician.
• Glucose self-monitoring: regular blood sugar measurement to assess treatment effectiveness.

Modern approaches to pharmacological treatment

If diet and exercise do not allow for reaching glycemic targets, pharmacological therapy is prescribed.

Traditionally, the primary medication is insulin, which is considered safe and effective during pregnancy.

In recent years, the use of metformin has been actively studied. A systematic review and meta-analysis, including 9 randomized controlled trials (RCTs) with 2420 women, showed that adding metformin to insulin (compared to insulin alone) reduces the risk of stillbirth in pregnant women with GDM or type 2 diabetes. This indicates moderate-quality evidence in favor of combination therapy [4].

New classes of drugs, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs), are showing promising results in the treatment of metabolic diseases. However, data on their safety and efficacy directly during pregnancy are still insufficient. Most available data are derived from retrospective studies of accidental exposure, and further analyses are needed to assess potential teratogenic effects, despite encouraging preclinical results [8].

The role of psycho-emotional support and new methods

A GDM diagnosis often causes anxiety, depression, and diabetes-specific distress in pregnant women. These psycho-emotional states can activate the hypothalamic-pituitary-adrenal axis, which in turn exacerbates insulin resistance and complicates glycemic control, creating a "psychometabolic vicious cycle" [1].

Mindfulness-Based Stress Reduction (MBSR) is being studied as an adjunctive therapy. This is an evidence-based intervention that promotes emotional regulation and increases stress resilience. Currently, a randomized controlled trial involving 300 pregnant women with GDM (at 24-28 weeks gestation) is underway to evaluate the effectiveness of an 8-week group MBSR program in improving glycemic control and psychological well-being [1].

Long-term consequences and postpartum prevention

GDM has long-term health consequences for both mother and child.

• For the mother: women who have had GDM have a significantly increased risk of developing T2DM in the postpartum period [3, 6]. Therefore, it is crucial to continue glucose monitoring and maintain a healthy lifestyle after delivery.
• For the child: children born to mothers with GDM are at an increased risk of developing metabolic disorders in the future [6].

To prevent the progression of prediabetes to T2DM in women after GDM, new strategies are being actively researched in the early postpartum period. For example, a multicenter, double-blind, randomized, placebo-controlled trial (SERENA) is evaluating the efficacy, safety, and cost-effectiveness of semaglutide (a GLP-1 receptor agonist) in this population. The study will involve 252 women with prediabetes after GDM [3]. GLP-1RAs may prevent the progression of GDM to T2DM in the postpartum period [8].

Important note: Gestational diabetes insipidus

It is important not to confuse gestational diabetes mellitus (GDM) with gestational diabetes insipidus. These are two completely different conditions. Gestational diabetes insipidus is a rare condition characterized by a disruption of the body's water balance, leading to excessive urine output (polyuria) and intense thirst (polydipsia) [2].

Gestational diabetes insipidus is often underdiagnosed because polyuria is frequently considered a normal phenomenon during pregnancy. However, this condition can be associated with serious underlying pathology, so physicians monitoring pregnant women should consider screening for gestational diabetes insipidus [2].

Sources

1. Mindfulness-Based Stress Reduction as an Adjunct Therapy for Gestational Diabetes Mellitus: A Randomized Controlled Trial Protocol. https://pubmed.ncbi.nlm.nih.gov/42609830/
2. Gestational diabetes insipidus: a review of an underdiagnosed condition. https://pubmed.ncbi.nlm.nih.gov/20500966/
3. Semaglutide for prevention of type 2 diabetes in women with postpartum prediabetes after gestational diabetes: protocol for a Belgian multicentre double-blind randomised placebo-controlled trial. https://pubmed.ncbi.nlm.nih.gov/42493207/
4. Metformin + Insulin vs. Insulin for GDM and T2DM during pregnancy: systematic review and meta-analysis. https://pubmed.ncbi.nlm.nih.gov/42500179/
5. Maternal diabetes subtypes and offspring cutaneous health: developmental programming of sebaceous gland function in over 330,000 live births. https://pubmed.ncbi.nlm.nih.gov/42138741/
6. How the First 9 Months Shape the Rest of Your Life: The Impact of Gestational Diabetes on the Metabolic Future. https://pubmed.ncbi.nlm.nih.gov/42305028/
7. Targeting metabolism to protect fertility and healthy pregnancy with SGLT2 inhibitors and GLP-1RAs. https://pubmed.ncbi.nlm.nih.gov/42272808/

The information provided in this article is for reference purposes only and cannot replace professional medical advice. Always consult your physician for diagnosis and treatment.